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ABSTRACT
Obligatory intracellular parasites such as Plasmodium sp, Trypanosoma cruzi, Toxoplasma gondii and Leish-
mania sp are responsible for the infection of hundreds of millions of individuals every year. These parasites
can deliver antigens to the host cell cytoplasm that are presented through MHC class I molecules to protec-
tive CD8 T cells. The in vivo priming conditions of specific CD8 T cells during natural infection are largely
unknown and remain as an area that has been poorly explored. The antiparasitic mechanisms mediated by
CD8 T cells include both interferon-γ -dependent and -independent pathways. The fact that CD8 T cells are
potent inhibitors of parasitic development prompted many investigators to explore whether induction of these
T cells can be a feasible strategy for the development of effective subunit vaccines against these parasitic
diseases. Studies performed on experimental models supported the hypothesis that CD8 T cells induced
by recombinant viral vectors or DNA vaccines could serve as the basis for human vaccination. Regimens
of immunization consisting of two different vectors (heterologous prime-boost) are much more efficient in
terms of expansion of protective CD8 T lymphocytes than immunization with a single vector. The results
obtained using experimental models have led to clinical vaccination trials that are currently underway.
Key words: CD8, parasites, immunity, vaccine.
INTRODUCTION
The population at risk of infection by obligatory in-
tracellular parasites is estimated at billions of in-
dividuals living mostly in tropical and subtropical
regions of the world where these parasites are en-
demic.
Plasmodium falciparum is responsible for the
larger burden of malaria, an estimated 300 million
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cases of the disease per year that result in the death
of more than 1 million people, mostly African chil-
dren under the age of five. Altogether, the other
most important intracellular parasites (Plasmodium
vivax, Trypanosoma cruzi, Toxoplasma gondii and
Leishmania sp) are not responsible for as many in-
fections or kill as many individuals as P. falciparum.
Nevertheless, they are responsible for infecting mil-
lions of individuals yearly causing enormous social
distress and economic losses.
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Although the pattern of disease transmission,
infection and mortality caused by these obligatory
intracellular parasites has changed in the past 50
years, worldwide they had never been a greater prob-
lem than they are today. In developing countries,
these circumstances are very unlikely to improve in
the next ten years. In view of these problems, the
development of new strategies for prevention and
control of these diseases are in great need.
Mass vaccination against these parasitic infec-
tions is not available. Research in this field can be
considered important because in the future vaccines
may complement other strategies such as chemo-
therapy, vector control etc., for the prevention and
control of these parasitic diseases. Based on this
conviction, studies on the mechanisms of host pro-
tective immunity and its target antigens have been
pursued by immuno-parasitologists for the last 50
years.
HISTORICAL BACKGROUND
Pioneering studies performed in the sixties by
Dr. Ruth S. Nussenzweig and collaborators at New
York University firmly established that immuniza-
tion with radiation-attenuated sporozoites could
confer an exceptional degree of protection against
experimental infection with viable sporozoites of
Plasmodium berghei, a species that causes malaria
in rodents. In the following decades, this work
was extended to several other host species includ-
ing humans. Individuals immunized with radiation-
attenuated sporozoites of P. falciparum develop a
protective immunity that is sterile, long lived and
prevents the development of any symptom of the
disease (Hoffman et al. 2002). Because of these
exceptional attributes, this type of immunity would
be ideal for an effective vaccine against malaria.
In 1987 and 1988, two groups independently
reported that the immunity induced in mice by
radiation-attenuated sporozoites was dependent on
CD8 T lymphocytes (Schofield et al. 1987, Weiss et
al. 1988). It was the first evidence that this subpop-
ulation of lymphocytes participates in the immunity
against any form of a parasite. In the subsequent
years, it was described that CD8 T cells also partic-
ipate in immunity to infections caused by other in-
tracellular parasites such as Toxoplasma gondii and
Trypanosoma cruzi. In the case of Leishmania sp,
the participation of CD8 T cells is more controver-
sial; however, very recent studies have implicated
CD8 T cells in the pathogenesis and immunity of
certain types of cutaneous infection (Belkaid et al.
2002).
The definition of the importance of CD8 T lym-
phocytes in the immunity against these intracellular
protozoan parasites has opened a new direction in
the studies of the immunologic mechanisms of re-
sistance to parasitic diseases. From a practical point
of view, it may have important implications in the
development of vaccines against these parasitic dis-
eases.
CD8 T CELLS AS AN IMPORTANT MECHANISM
MEDIATING PROTECTIVE IMMUNITY AGAINST
INTRACELLULAR PARASITIC INFECTIONS
Malaria Liver Stages
The importance of CD8 T lymphocytes in the resis-
tance to infection against a challenge with malaria
sporozoites was demonstrated in several studies per-
formed during the last 15 years. In initial studies,
BALB/c mice immunized with radiation-attenuated
sporozoites were depleted of CD8 T cells before a
challenge with viable sporozoites of P. yoelii. CD8-
depleted immunized mice became completely sus-
ceptible to infection (Weiss et al. 1988). This study
demonstrated that in the absence of CD8 T lympho-
cytes, other immunological mechanisms induced by
radiation-attenuated sporozoites were not capable to
promote resistance against the infection.
To further study the importance of CD8 T cells
in the immunity to experimental malaria, T cell
clones were obtained from spleen cells of BALB/c
mice immunized with radiation-attenuated P. yoelii
sporozoites. CD8 T cell clones were generated and
characterized in vitro in terms of phenotype and
specificity. These clones were Thy1+, αβ T-Cell
Receptor+, CD4- and CD8+ and they recognized
An Acad Bras Cienc (2003) 75 (4)
ROLE OF CD8 T CELLS DURING PARASITIC INFECTIONS 445
with high affinity a synthetic peptide represented by
amino acids SYVPSAEQI present in the C-terminal
portion of P. yoelii CS protein (Rodrigues et al.
1991).
In vitro these CD8 T cells presented intense
lytic activity and capacity of inducing DNA degra-
dation of H-2kd target cells in the presence of the
malaria peptide. In addition, these cells secrete large
amounts of IFN-γ , TNF-α and the enzyme BLT-
esterase when stimulated by the antigen in vitro (Ro-
drigues et al. 1991, 1992). Most important, when
adoptively transferred to naïve BALB/c mice, some
of these clones were capable to provide specific im-
munity against the challenge with viable P. yoelii
sporozoites (Rodrigues et al. 1991, 1992).
To demonstrate that liver stages of the malaria
parasite were in fact targets for the immunity me-
diated by these CD8 T lymphocytes, an assay was
developed to quantify the P. yoelii rRNA in RNA
isolated from livers of mice infected with P. yoelii.
Using this assay it was possible to demonstrate that
there was a reduced amount of parasite rRNA in the
liver of animals that received cells of a CD8 T cell
clone 20 hours after the challenge with sporozoites.
In contrast, control animals that did not receive T
cells presented large amounts of parasite rRNA in
their livers (Rodrigues et al. 1991).
CD8 T cells specific for epitopes present
within the P. falciparum liver stage antigens
have been commonly observed in humans immu-
nized with radiation-attenuated sporozoites of P. fal-
ciparum (Doolan et al. 1997). Whether these cells
are as important for human protective immunity as
seen in the mouse model of infection cannot be di-
rectly addressed experimentally. Nevertheless, it is
very likely that they actively participate in the pro-
tective immunity observed in human vaccinees.
During natural infection in humans, CD8 T
cells specific for epitopes present within different
plasmodial antigens have been detected in many in-
dividuals with previous contact with P. falciparum
(Hill et al. 1992, Aidoo et al. 1995, Plebanski et al.
1997, Gonzalez et al. 2000). Because these indi-
viduals do not develop sterile immunity against re-
infection, these CD8 T cells do not seem to provide
a degree of protective immunity similar to the one
observed in individuals vaccinated with radiation-
attenuated sporozoites of P. falciparum. Whether
this is a matter of specificity or quantity of specific
T cells it is unknown. Alternatively, mechanisms
of parasite evasion of the immune response that are
absent after immunization with radiation-attenuated
sporozoites of P. falciparum may operate during nat-
ural human infection.
Trypanosoma cruzi
The importance of CD8 T cells in the nat-
urally acquired immunity to T. cruzi infection was
determined by the use of genetically modified mice
that do not express either MHC class I or the CD8
molecule. These two genetically deficient mouse
strains are highly susceptible to infection, being un-
able to control acute parasitemia (Tarleton et al.
1992, Rottenberg et al. 1993).
Subsequent studies generated CD8 T-cell lines
specific for an epitope of trypomastigote surface
antigen-1 (TSA). These T-cell lines were Thy1+,
αβ T-cell receptor+, CD4- and CD8+. In vitro these
CD8 T cells presented intense lytic activity against T.
cruzi-infected target cells. These cells also secreted
large amounts of IFN-γ and TNF-α when stimulated
with the antigen in vitro (Wizel et al. 1997). When
adoptively transferred to naïve mice, they provided
specific immunity against the challenge with infec-
tive forms of T. cruzi (Wizel et al. 1997).
T. cruzi is a parasite that persists for long pe-
riods of time causing a chronic inflammatory dis-
ease. Under certain circumstances T cells exacer-
bate the immune response causing an increase in
tissue pathology or autoimmunity (Soares et al.
2001a). However, this autoimmune response has
been associated with CD4 Th1 cells (dos Santos et
al. 1992, Soares et al. 2001b).
As mentioned above, in the murine model,
the adoptive transfer of large amounts of IFN-γ -
producing CD8 T cells specific for a parasite epi-
tope significantly reduced infection and promoted
survival of mice against a lethal infection with T.
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cruzi (Wizel et al. 1997). These results indicate that
IFN-γ -producing CD8 T cells did not aggravate in-
flammatory reactions or autoimmunity, but rather
promoted elimination of the parasites.
During natural infection in humans, CD8 T
cells specific for T. cruzi have been detected in most
individuals in the chronic phase of infection (Wizel
et al. 1998b). Also, there is an association of an
increase in CD8 T cells with the presence of T. cruzi
antigens in chronic human chagasic myocarditis
(Higuchi et al. 1997).
Although it is difficult to prove definitively that
these cells are important in host resistance, it is plau-
sible to believe that they exert an antiparasitic role
similar to that seen in the mouse model of infection.
Toxoplasma gondii
Early studies by the group of Kasper and collabora-
tors demonstrated that mice and humans immune to
T. gondii develop CD8 T cells that recognize para-
site antigen presented by antigen-pulsed or infected
target cells. These CD8 lymphocytes proliferate, se-
crete IFN-γ , lyse the target cells and block the mul-
tiplication of parasites in vitro (Khan et al. 1988,
1990).
In subsequent years, the concept that CD8 T
cells are a very important effector mechanism
against this parasitic infection became well estab-
lished (reviewed by Denkers and Gazzinelli 1998).
In mice vaccinated with an attenuated strain of T.
gondii (ts-4), the depletion of CD8T cells was shown
to partially abrogate resistance to infection with a
highly virulent strain of the parasite. Among the αβ
T lymphocytes, CD8 T cells seem to be the major
effector mechanism because the depletion of CD4 T
cells fails to produce any detectable loss of immu-
nity. Nevertheless, both subpopulations of T lym-
phocytes cooperate in the immune response because
the depletion of CD4 and CD8 T cells renders mice
immunized with attenuated T. gondii ts-4 completely
susceptible to infection (Gazzinelli et al. 1991).
The importance of CD8 T cells in the resistance
to murine toxoplasmosis was confirmed in parallel
studies in which CD4-depleted T lymphocytes were
adoptively transferred to naïve athymic recipients.
These cells (mainly CD8 cells) led to a significant
increase in mouse survival after infection and a sig-
nificant reduction in the formation of brain cysts
(Parker et al. 1991). Finally, the importance of CD8
T cells was demonstrated by the adoptive transfer of
T cell clones specific for a T. gondii antigen. αβ T-
cell receptor+, CD4- and CD8+ T cells specific for
the P30 (Sag1) antigen conferred a high degree of
protective immunity against a lethal challenge with
T. gondii (Khan et al. 1994).
Several lines of evidence implicate T lympho-
cytes in pathologic changes associated with acute
infection in mice. Most evidence pointed at lym-
phocytes of the CD4 subset and granulocytes dur-
ing this detrimental inflammatory response that can
be the cause of death. Therefore, so far, CD8 T
cells seem to be associated with a particularly ben-
eficial immune response by the host, being unable
to cause significant pathology (reviewed by Denkers
and Gazzinelli 1998).
Leishmania sp.
Years of studies have been unable to firmly establish
that CD8 T cells are required for naturally acquired
immunity against Leishmania sp. This is not un-
expected because it is well established that MHC
class II restricted CD4 T cells are extremely dom-
inant during the development of immunity against
Leishmania sp. The importance of CD4 T cells was
illustrated in studies using mice deficient for the ex-
pression of CD8 or class II MHC molecules. After
primary subcutaneous infection with L. major, CD8-
deficient mice controlled the infection for over 1 year
(Huber et al. 1998). On the other hand, mice geneti-
cally deficient for MHC class II are highly suscepti-
ble to infection (Locksley et al. 1993). These results
support the notion that in the absence of CD8 T cells,
other cell types (mainly class II restricted helper T
cells) could provide an efficient control of a primary
infection with L. major.
In spite of these earlier observations, very re-
cent studies using low doses of L. major promastig-
otes inoculated into a dermal site (ear dermis) de-
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monstrated that CD8 T-cell-deficient mice failed to
control parasite growth. Also, these animals had
a minor and delayed dermal pathology when com-
pared to wild-type animals. In this model of infec-
tion, reconstitution of resistance was obtained when
both CD4 and CD8 T cells were adoptively trans-
ferred. This study strongly suggests that CD8 T
lymphocytes participate in both the pathology and
immunity to primary infection with L. major in the
skin (Belkaid et al. 2002).
These results are in agreement with a number of
previous observations indicating that specific CD8
T cells are primed during natural infection or vacci-
nation in humans. When re-stimulated in vitro with
Leishmania antigens, human CD8 T cells secrete
IFN-γ , an important mediator of resistance against
certain types of infection with Leishmania sp (De
Luca et al. 1999, Bottrel et al. 2001, Pompeu et al.
2001). Also, in individuals that develop the mucocu-
taneous form of the disease, CD8 T lymphocytes are
highly cytolytic in vitro against Leishmania-infected
macrophages (Brodskyn et al. 1997).
Together with the evidence obtained recently
with the murine model of infection, it seems that
CD8 T cells participate in both the pathogenesis and
immunity to cutaneous and mucocutaneous Leish-
maniasis. Nevertheless, the importance of these
cells in relation to CD4 T cells is far from clear and
remains to be further elucidated.
IDENTIFICATION OF THE EPITOPES
RECOGNIZED BY PROTECTIVE CD8 T CELLS
IN MICE AND HUMANS
Malaria Liver Stages
Initial studies using the mouse model of malaria
searched for CD8 epitopes in the only protein that
had its primary structure known at that time, the CS
protein. As a source of CD8 lymphocytes, spleen
cells of mice vaccinated with radiation-attenuated
sporozoites were used because these animals de-
velop strong protective immunity against the infec-
tion. So far, to our knowledge, in mice vaccinated
with radiation-attenuated sporozoites, CD8 lympho-
cytes were specific for a single epitope found in the
C-terminal region of the P. berghei or P. yoelii CS
protein (Romero et al. 1989, Rodrigues et al. 1991,
1992). This epitope is recognized by CD8 T cells
restricted by H-2 Kd molecules.
Figure 1 shows an outline of the P. yoelii CS
protein with its different immunodominant epitopes
recognized by antibodies (lymphocytes B) or CD4
or CD8 T lymphocytes. The epitopes of P. yoelii
CS protein are important because the infectivity of
P. yoelii sporozoites is comparable to that of P. fal-
ciparum, the most virulent human malaria parasite.
Due to these characteristics, P. yoelii infection in
mice is considered a valuable model for studies of
preclinical development of subunit vaccines (see be-
low).
Similar to the mouse studies, epitopes recog-
nized by human CD8 T cells from individuals vac-
cinated with radiation-attenuated sporozoites of P.
falciparum were initially identified within the CS
protein of this human malaria parasite (Malik et
al. 1991). In subsequent studies, CD8 epitopes
were also found in several other distinct antigens
expressed in liver stages of P. falciparum (Doolan
et al. 1997, Wizel et al. 1995a,b, Kumar et al.
2001). Currently a total of 35 epitopes have been
described in different liver stage proteins of P. fal-
ciparum recognized by CD8 T cells from individu-
als of diverse HLA haplotypes vaccinated with
radiation-attenuated sporozoites (Table I).
In addition to CD8 epitopes recognized by
T cells from individuals vaccinated with radiation-
attenuated sporozoites, other epitopes were deter-
mined using cells collected from individuals natu-
rally exposed to malaria (Hill et al. 1992, Aidoo
et al. 1995, Plebanski et al. 1997). A list of the
CD8 epitopes described in the distinct liver stage
antigens of P. falciparum is depicted in Table II. As
can be noticed, some of these epitopes are common
to the ones mapped in individuals vaccinated with
radiation-attenuated sporozoites. New epitopes rec-
ognized by individuals of the HLA-A2.1 haplotype
have been recently described suggesting that the
number of CD8 epitopes might be underestimated
(Gonzalez et al. 2000).
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TABLE I
Epitopes on P. falciparum liver stage proteins recognized by CD8 T cells from volunteers
vaccinated with radiation-attenuated sporozoites of P. falciparum.
Protein Residues HLA Sequence Ref.
CS 368-390 KPKDELDYENDIEKKICKMEKCS Malik et al. 1991
CS 310-319 A1.31 EPSDKHIKE Kumar et al. 2001
CS 394-402 A2.386 GLIMVLSFL Doolan et al. 1997
CS 7-16 A2.7 ILSVSSFLFV Doolan et al. 1997
CS 344-353 A3/11.336 VTCGNGIQVR Doolan et al. 1997
CS 285-294 B7.285 MPNDPNRNV Doolan et al. 1997
TRAP 1-15 A2 MNHLGNVKYLVIVFL Wizel et al. 1995b
TRAP 46-60 A2 EVDLYLLMDCSGSIR Wizel et al. 1995b
TRAP 121-135 A2 LLSTNLPYGKTNLTD Wizel et al. 1995b
TRAP 126-140 A2 LPYGKTNLTDALLQV Wizel et al. 1995b
TRAP 131-145 A2 TNLTDALLQVRKHLN Wizel et al. 1995b
TRAP 136-150 A2 ALLQVRKHLNDRINR Wizel et al. 1995b
TRAP 221-235 A2 ENVKNVIGPFMKAVC Wizel et al. 1995b
TRAP 281-295 A2 CEEERCLPKREPLDV Wizel et al. 1995b
TRAP 286-300 A2 CLPKREPLDVPDEPE Wizel et al. 1995b
TRAP 521-535 A2 ALLACAGLAYKFVVP Wizel et al. 1995b
TRAP 546-560 A2 APFDETLGEEDKDLD Wizel et al. 1995b
TRAP 551-565 A2 TLGEEDKDLDEPEQF Wizel et al. 1995b
TRAP 107-115 B8 ASKNKEKAL Kumar et al. 2001
TRAP 109-117 B8 KNKEKALII Kumar et al. 2001
TRAP 14-23 A2 FLIFFDLFLV Doolan et al. 1997
TRAP 522-531 A3 LLACAGLAYK Doolan et al. 1997
TRAP 523-531 A3 LACAGLAYK Doolan et al. 1997
TRAP 539-548 B7 TPYAGEPAPF Doolan et al. 1997
EXP1 80-88 A2 VLAGLLGNV Doolan et al. 1997
EXP1 2-10 A2 KILSVFFLA Doolan et al. 1997
EXP1 83-91 A2 GLLGNVSTV Doolan et al. 1997
EXP1 91-100 A2 VLLGGVGLVL Doolan et al. 1997
EXP1 10-18 A3 ALFFIIFNK Doolan et al. 1997
LSA1 94-102 A3 QTNFKSLLR Doolan et al. 1997
LSA1 105-113 A3 GVSENIFLK Doolan et al. 1997
LSA1 59-68 A3 HVLSHNSYEK Doolan et al. 1997
LSA1 11-20 A3 FILVNLLIFH Doolan et al. 1997
PfS16 77-85 B7 MPLETQLAI Doolan et al. 1997
Adapted from Kumar et al. 2001. Abbreviations: CS (circumsporozoite protein), TRAP (Thrombospondin
Related Anonymous Protein), EXP1 (Excreted Protein-1), LSA1 (Liver Stage Antigen-1) and PfS16 (P. falci-
parum Surface antigen of 16 kDa).
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Fig. 1 – CS protein of Plasmodium yoelii.
TABLE II
Epitopes on P. falciparum liver stage proteins recognized by CD8 T cells from indi-
viduals naturally exposed to sporozoites of P. falciparum
Protein Residues HLA Sequence Responder / Ref.
total
CS 368-375 B35 KPKDELDY 3/15 Hill et
KSKDELDY 1/10 al. 1992
CS 300-308 B7 MPNDPNRNV 1/6 Aidoo et al. 1995
CS 105-13 B8 LRKPKHKKL 2/11 Aidoo et al. 1995
TRAP 3-11 A2.1 HLGNKYLV 2/7 Aidoo et al. 1995
TRAP 500-08 A2.1 GIAGGLALL 2/7 Aidoo et al. 1995
TRAP 107-15 B8 ASKNKEKAL 1/11 Aidoo et al. 1995
TRAP 109-17 B8 KNKEKALII 2/11 Aidoo et al. 1995
LSA1 1786-94 B53 KPIVQYDNF 4/14 Hill et al. 1992
LSA1 1850-7 B35 KPNDKSLY 1/15 Hill et al. 1992
LSA1 1854-61 B17 KSLYDEHI 2/5 Aidoo et al. 1995
STARP 523-31 A2.2 MINAYLDKL 1/5 Aidoo et al. 1995
Adapted from Aidoo et al. 1995 and Plebanski et al. 1997. Abbreviations: CS (circumsporozoite
protein), TRAP (Thrombospondin Related Anonymous Protein), LSA1 (Liver Stage Antigen-1)
and STARP (sporozoite threonine/asparagine-rich protein).
The identification of these CD8 epitopes is the
basis for the development of multi-antigen subunit
vaccines aimed at the induction of CD8 T cells in
humans (see below).
Trypanosoma cruzi
Spleen cells from mice chronically infected with T.
cruzi were used to identify a number of epitopes
recognized by mouse H-2Kb restricted CD8 T cells.
These epitopes were located within the trypomastig-
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ote surface antigen-1 (TSA-1) and amastigote sur-
face protein -1 or 2 (ASP-1 or ASP2, respectively,
Wizel et al. 1997, Low et al. 1998). In addition, a
CD8 T cell epitope was located in the trans-sialidase
of T. cruzi by using spleen cells from mice immu-
nized with plasmid DNA (Rodrigues et al. 1999).
Table III contains a list of the murine CD8 epitopes
that have been described so far.
Similar to mice, humans with the HLA-A2.1
haplotype chronically infected with T. cruzi also dis-
played CD8 T cells specific for epitopes within the
TSA-1,ASP-1 orASP-2 antigen (Wizel et al. 1998b,
Table IV). Recently, epitopes recognized by humans
with the HLA-A2.1 haplotype have been determined
in the trypomastigote-secreted antigens FL-160 and
cruzipain (E. Cunha-Neto, personal communica-
tion).
Toxoplasma gondii and Leishmania sp.
Few publications have studied the antigens that are
target of CD8 T cells specific for T. gondii. Khan
et al. (1988), using spleen cells from infected mice,
demonstrated the presence of CD8 T cells specific
for the purified membrane protein denominated P30
or Surface Antigen 1 (SAG1). This result was con-
firmed by the immunization with native protein that
elicited protective immunity dependent on the acti-
vation of this subpopulation of lymphocytes (Khan
et al. 1991). CD8 T cell clones specific for the puri-
fied P30 antigen (SAG1) were generated and, when
adoptively transferred to naive mice, protected them
against acute infection with T. gondii (Khan et al.
1994).
In recent studies a putative CD8 T cell epitope
recognized by spleen cells of mice immunized with a
plasmid DNA containing the SAG1gene was iden-
tified. This epitope is represented by amino acids
AESKSVII and it is possibly recognized by CD8 T
cells restricted by H-2Kk (Nielsen et al. 1999).
In humans with the HLA-A*0201 haplotype,
one epitope recognized by CD8 T cells was also
identified within the SAG1 antigen. A peptide rep-
resenting amino acids 289-297 (SPEKHHCTV) was
recognized by HLA-A*0201 restricted human CD8
T cells that lysedT. gondii-infected target cells (Yano
et al. 1997).
CD8 T cells specific for a single antigen
(GP46/M-2) expressed in Leishmania amazonen-
sis were shown to recognize Leishmania-infected
macrophages (Kima et al. 1997). However, no sub-
sequent epitope mapping was performed.
CONDITIONS OF IN VIVO PRIMING AND
EXPANSION OF PROTECTIVE CD8 T CELLS
The immune response is initiated when antigenic
fragments (epitopes) of pathogen-derived proteins
are presented by the molecules of the major histo-
compatibility complex (MHC). While MHC class I
products are responsible for the presentation to clas-
sic CD8 cytotoxic T cells, MHC class II products
will prime classic CD4 helper T cells.
Entry into the class I-restricted pathway
of antigen presentation usually occurs through the
presence of the antigenic proteins in the cytosol of
antigen- presenting cells. In addition, dendritic cells
can ingest proteins and have them processed and pre-
sented by the MHC class I pathway. The MHC class
II pathway is mostly centered on peptides generated
in the endocytic pathway. A detailed description
of the MHC class I or class II pathways of antigen
presentation can be found elsewhere (reviewed by
Ploegh 1998).
The conditions of priming and expansion of
CD8 T cells specific for any of these parasitic anti-
gens during infection are completely obscure. It is
unknown whether priming occurs through infection
or antigen-pulsing of antigen-presenting cells, or by
cross priming. Cross priming occurs when den-
dritic cells or macrophages take up cell-associated
antigens and present them in the context of MHC
class I molecules to classic CD8 T cells. This path-
way of antigen presentation is particularly important
when the antigen is not expressed in dendritic cells
or macrophages. It will be very important in the fu-
ture to characterize in detail the priming conditions
of CD8 T cells specific for the different parasitic
antigens.
The role of CD4 T cells in the priming and/or
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TABLE III
Epitopes of Trypanosoma cruzi recognized by mouse CD8 T cells.
Peptide Protein Residues H2 Sequence Ref.
Pep77.2 TSA-1 515-522 Kb VDYNFTIV Wizel et al. 1997
PA14 ASP-1 509-516 Kb VNHDFTVV Low et al. 1998
PA5 ASP-2 285-292 Kb KNYPFSSI Low et al. 1998
PA6 ASP-2 274-281 Kb NTLVFPLV Low et al. 1998
PA7 ASP-2 545-552 Kb DNRQYSFV Low et al. 1998
PA8 ASP-2 552-559 Kb VNHRFTLV Low et al. 1998
PA10 ASP-2 399-409 Db/Kb EKEANALYLWV Low et al. 1998
TS359-367 TCTS 359-367 Kd IYNVGQVSI Rodrigues et al. 1999
P5 LYT1 190-198 Kb ELTMYKQLL Fralish and Tarleton 2003
Adapted from Low et al. 1998. Abbreviations: TSA-1 (Trypomastigote SurfaceAntigen-1),ASP-1(Amastigote
Surface Protein-1), ASP-2 (Amastigote Surface Protein-2) and TCTS (T. cruzi trans-sialidase).
expansion of specific CD8 T cells was addressed in
few studies. CD4 T cells were important for the de-
velopment of CD8 T cells specific for both T. gondii
and malaria parasites (Gazzinelli et al. 1991, Parker
et al. 1991). In the case of malaria (P. yoelii), it was
possible to elegantly demonstrate that IL-4 secreted
by CD4 T cells was crucial for the maturation, but
not for the initial proliferation of specific CD8 T
cells (Carvalho et al. 2002).
CHARACTERIZATION OF THE IN VIVO EFFECTOR
MECHANISMS MEDIATED BY PROTECTIVE CD8 T
CELLS
Malaria Liver Stages
To elucidate the role of IFN-γ as an immunolog-
ical mechanism used by CD8 T cells to eliminate
the liver stages of malaria parasites in vivo, studies
were performed in mice genetically deficient for the
IFN-γ receptor. After a single dose of radiation-
attenuated sporozoites, these mice do not develop
protective immunity against malaria liver stages. In
contrast, wild type mice display remarkable
immunity against these forms of malaria (Tsuji et
al. 1995). This experimental evidence strongly
argues for the fact that after a single immuniza-
tion with radiation-attenuated sporozoites, CD8 T
cells use IFN-γ -dependent mechanism(s) to elimi-
nate malaria liver stages. Because IFN-γ is a potent
inducer of nitric oxide (NO) in mice, a similar ap-
proach was used to determine whether NO could
mediate elimination of malaria liver stages. Un-
expectedly, NO synthase 2 (NOS2)-deficient mice
develop protective immunity in a manner similar to
wild type animals (M. Tsuji, personal communica-
tion).
In spite of the IFN-γ dependence detected af-
ter a single immunization with radiation-attenuated
sporozoites, after several doses of this immunogen,
strong protective immunity can develop in mice ge-
netically deficient for the IFN-γ receptor (Tsuji et al.
1995). The presence of IFN-γ independent mecha-
nisms was confirmed by the observations that CD8
T cell clones, as well as CD8 T cells induced by
immunization with a recombinant adenovirus, did
not require a functional IFN-γ receptor to eliminate
liver stages of P. yoelii (Rodrigues et al. 2000a). The
downstream molecules activated by IFN-γ , as well
as the nature of the IFN-γ -independent mechanisms
remains completely unknown at present.
Trypanosoma cruzi
Although there are several lines of evidence showing
that CD8 T cells participate in the protective immu-
nity against experimental T. cruzi infection, the pre-
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TABLE IV
Epitopes on T. cruzi proteins recognized by CD8 cells from
individuals HLA-A2.1 chronically infected.
Peptide Sequence Frequency of responders
Positive/total %
TSA-1(818-826) VLLPSLFLL 3/4 75
TSA-1(818-827) VLLPSLFLLL 18/21 86
TSA-1(89) KLFPEVIDL 9/13 69
TSA-1(514) FVDYNFTIV 17/21 81
ASP-1(668) LLGLWGLTGL 14/18 78
ASP-1(666) LLLLGLWGL 3/4 75
ASP-1(50) VLAKDGTEV 13/18 72
ASP-1(71) IAGGVMAVV 4/4 100
ASP-1(508) FVNHDFTVV 6/7 86
ASP-2(302) WVFPESISPV 4/4 100
ASP-2(551) FVNHRFTLV 1/4 25
Adapted from Wizel et al. 1998b. Abbreviations: TSA-1 (Trypo-
mastigote Surface Antigen-1), ASP-1(Amastigote Surface Protein-1),
ASP-2 and (Amastigote Surface Protein-2) .
cise mechanism(s) used by these cells to eliminate
T. cruzi has(ve) not been defined.
The fact that CD8 T cells secrete IFN-γ may
suggest that this mechanism may be relevant to the
elimination of intracellular forms of the parasite.
IFN-γ is an important mediator of naturally acquired
immunity against the infection. Genetically defi-
cient mice that do not express the IFN-γ recep-
tor or Stat4 are unable to control T. cruzi infection
(Holscher et al. 1998, Tarleton et al. 2000). How-
ever, a direct link between IFN-γ secretion by CD8
T cells and the in vivo antiparasitic activity of these
cells has not been provided so far.
The IFN-γ -dependent mechanisms are at least
in part mediated by the production of NO. In the
absence of IFN-γ receptors, NO is not produced
by macrophages, suggesting that IFN-γ is the
main inducer of NOS2 activation. The evidence that
NO is critical for the elimination of T. cruzi during
acute experimental infection was obtained with ge-
netically deficient mice that do not express NOS2.
These animals are highly susceptible to infection
with different parasite strains (Holscher et al. 1998,
Rodrigues et al. 2000b).
In addition to producing IFN-γ , CD8 T cells
can lyse host cells infected with T. cruzi, or se-
crete other potentially active mediators such as TNF-
α, granulisin or a number of different chemokines
(Munoz-Fernandez et al. 1992, Aliberti et al. 1999,
Stenger et al. 1999). In fact, CD8 T cells specific
for amastigote or trypomastigote antigens are capa-
ble of lysing non-phagocytic cells infected with T.
cruzi in vitro (Wizel et al. 1997, Low et al. 1998).
However, it is unclear whether lysis and DNA degra-
dation of infected target cells by CD8 T cells can be
an effective mechanism to restrain T. cruzi infec-
tion in vivo. Genetically deficient mice that do not
express perforin or granzyme B are not more sus-
ceptible to infection than wild type animals (Kumar
and Tarleton 1998). These observations argue for
the fact that in the absence of perforin- or granzyme
B-mediated lysis other mechanism(s) can provide
resistance against T. cruzi infection in mice. The
elucidation of the anti-parasitic mechanisms medi-
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ated by T. cruzi-specific CD8 T cells will require fur-
ther investigation using more complex experimental
models.
Toxoplasma gondii
The participation of IFN-γ as an important immuno-
logical mechanism used by immune cells to elimi-
nate tachyzoites of T. gondii was determined initially
by the treatment of mice with specific neutralizing
monoclonal antibodies. Mice injected with a mono-
clonal antibody to IFN-γ succumb due to acute toxo-
plasmosis. In contrast, animals that received control
antibodies survived infection and developed chronic
infection (Suzuki et al. 1988). In subsequent stud-
ies, it was shown that treatment with neutralizing
monoclonal antibodies had the ability to dramati-
cally change the resistant phenotype of mice vacci-
nated with an attenuated strain of T. gondii (Gazz-
inelli et al. 1991). Using genetically modified mice
that do not express IFN-γ , it became clear that this
cytokine is crucial for the resistance against acute
toxoplamosis in mice (Denkers et al. 1997). Be-
cause the resistance elicited by vaccination with at-
tenuated parasites had been previously thought to be
partially dependent on CD8 T cells, it was plausible
to assume that the IFN-γ was secreted in part by
these cells.
However, the most compelling evidence show-
ing the importance of IFN-γ produced by CD8 T
cells in mediating resistance to murine acute toxo-
plasmosis was obtained by the adoptive transfer of
protective immunity by CD8 T cell clones specific
for T. gondii. The treatment with specific neutral-
izing monoclonal antibodies to mouse IFN-γ com-
pletely reversed the immunity mediated by these T
cells in naïve mice (Khan et al. 1994).
The IFN-γ secreted by CD4, CD8 and NK cells
has the ability to activate in vivo nonhematopoi-
etic or hematopoietic cells to eliminate intracellu-
lar T. gondii parasites. Using mouse bone marrow
chimeras between wild-type and IFN-γ receptor-
deficient mice, Yap and Sher (1999) elegantly de-
monstrated that both cell types have to express the
IFN-γ receptor to provide efficient immunity to
acute and persistent infection.
Because IFN-γ is a major inducer of NO syn-
thesis by phagocytic cells, the participation of NOS2
was evaluated with the aid of genetically modified
mice deficient for the expression of this enzyme.
NOS2-deficient mice infected with an aviru-
lent strain of T. gondii die at approximately 21 to
30 days postinfection. Death was associated with
large numbers of cysts and tachyzoites suggesting
the importance of NO in the control of chronic in-
fection. A similar observation was made in mice
genetically deficient for IFN-γ Regulatory Factor-1,
the main regulator of IFN-γ -induced NO (reviewed
by Denkers and Gazzinelli 1998).
Using mouse bone marrow chimeras between
wild type and NOS2-deficient mice, it was possi-
ble to determine that NO synthesis was important
for the control of tachyzoite replication in infected
hematopoietic but not in non-hematopoietic cells
(Yap and Sher 1999).
In spite of the importance of reactive nitrogen
intermediates in the control of the chronic stage of
infection, several lines of evidence strongly indi-
cate that IFN-γ induces other antiparasitic mecha-
nisms independent of NO during murine toxoplas-
mosis. First, IFN-γ -deficient mice die much ear-
lier (less than 10 days post-infection) than NOS2-
deficient animals. Also, NOS2-deficient mice vac-
cinated with the ts-4 strain were protected against
a challenge with a virulent T. gondii strain (Khan
et al. 1998). This protective immunity had been
previously shown to be entirely dependent on IFN-
γ (Denkers and Gazzinelli 1998). Finally, non-
hematopoietic cells deficient in the expression of
NOS2 can efficiently control parasite multiplication
in vivo (Yap and Sher 1999).
Other possible mechanisms operating in vivo
in the control of acute toxoplasmosis can be the re-
lease of reactive oxygen intermediates or tryptophan
degradation (reviewed by Denkers and Gazzinelli
1998). There is also evidence of a third still un-
known mechanism of intracellular T. gondii elimi-
nation. Murine astrocytes can be activated by IFN-
γ to eliminate intracellular forms of T. gondii. The
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elimination of these parasites does not depend on
reactive oxygen intermediates, NO or tryptophan
degradation (Halonen and Weiss 2000). Whether
or not these mechanisms operate in vivo and which
one is the most relevant is still unknown.
As mentioned above, in addition to secreting
IFN-γ , T. gondii-specific CD8 effector lymphocytes
from immune mice or humans are capable of effi-
ciently lysing parasite-infected target cells. The re-
quirement for IFN-γ in immunity to T. gondii has
made it difficult to evaluate the contribution of the
lytic activity of CD8 T cells to the resistance to in-
fection.
To determine the importance of perforin as a
mediator of the CD8 T cell-mediated immune re-
sponse, perforin-deficient mice were infected with
T. gondii. After vaccination with the ts-4 strain, re-
sistance to acute infection was as good in perforin-
deficient mice as in wild type animals. In the chronic
phase of infection there was a 3- to 4-fold increase
in the number of cysts in mice infected with a non-
lethal strain of T. gondii. This result indicates that
a perforin-mediated mechanism may operate in the
elimination of the brain cysts observed during the
chronic stages of mouse infection (Denkers et al.
1997).
GENERATION OF SUBUNIT VACCINES CONTAINING
EPITOPES RECOGNIZED BY PROTECTIVE CD8 T
CELLS AND PRECLINICAL EFFICACY TRIALS IN
EXPERIMENTAL MODELS
Malaria Liver Stages
The fact that CD8 T cells are potent inhibitors of
malaria liver stages and the characterization of epi-
topes recognized by these CD8 T lymphocytes
prompted many investigators to explore whether in-
duction of these T cells by subunit vaccines could be
a feasible strategy for vaccination against malaria.
A number of delivery systems have been used thus
far to induce mouse CD8 T lymphocytes specific
for the malarial epitope. They include recombinant
viruses, bacteria, plasmid DNA, virus-like particles
and synthetic peptides.
Recombinant viruses are the single class of im-
munogens that have been most systematically stud-
ied. Several recombinant viruses were used as vec-
tors to elicit specific CD8 T cells and protective im-
munity in BALB/c mice against a challenge with
sporozoites of P. yoelii. From these studies it be-
came clear that, when used individually, distinct vi-
ral vectors expressing a malarial CD8 epitope pro-
vided variable degrees of protective immunity
against liver stages of P. yoelii (reviewed by Soares
and Rodrigues 1998).
When used alone in a single immunization
dose, the replication-defective recombinant aden-
ovirus containing the entire P. yoelii CS protein gene
was shown to be the most efficient vector capable
of reducing the development of liver stages of P.
yoelii by ∼ 94%. Immunity was largely mediated
by CD8 T lymphocytes, but CD4 T cells also par-
ticipate in this process. Nevertheless, complete pro-
tection against malaria could only be observed in
40% of the mice challenged with P. yoelii sporo-
zoites (Rodrigues et al. 1997). In very recent stud-
ies, the immunogenicity and protective efficacy of
the recombinant adenoviral vector was improved by
a simultaneous injection of the Natural Killer T cell
ligand α-galactosylceramide. Under these circum-
stances, complete protection against infection with
P. yoelii sporozoites was achieved in 80% of BALB/c
mice (Gonzalez-Aseguinolaza et al. 2002).
Immunization with other recombinant viruses
elicited CD8 T cells specific for the malarial epi-
tope; however, the degree of elimination of malaria
liver stage was lower than that observed with the
adenoviral vector. Table V summarizes the results
obtained after a single immunization with a variety
of recombinant viral vectors.
Due to the limited degree of protective immu-
nity observed after immunization with a single re-
combinant virus, studies were performed to improve
protective immunity using sequential immunization
with two different viral vectors expressing the same
CD8 T-cell epitope for priming and boosting. This
strategy has been denominated heterologous prime-
boost immunization regimen.
Earlier studies performed with recombi-
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TABLE V
Summary of experiments using a single recombinant virus to elicit immunological elimination of liver
stages of Plasmodium yoelii.
Recombinant Foreign gene Liver Complete Immunological Reference
virus stage protection mechanism of
inhibition of BALB/c protection
mice
Adenovirus + Entire CS protein >95% 80% CD8 and CD4 T cells Gonzalez-
α-galactosyl Aseguinolaza
ceramide et al. 2002
Adenovirus Entire CS protein 94% 40% CD8 and CD4 T cells Rodrigues et al. 1997
Sindbis CD8 epitope ∼ 75% 0% CD8 T cells Tsuji et al. 1998
Vaccinia CD8 epitope ∼ 75% 0% CD8 T cells Rodrigues et al. 1994
Vaccinia Entire CS protein ∼ 55% 0% ? Li et al. 1993
Influenza CD8 epitope <10% 0% None Li et al. 1993
nant viruses expressing the P. yoelii malarial epi-
tope showed that heterologous prime-boost immu-
nization with recombinant influenza virus followed
by recombinant vaccinia virus elicited a high de-
gree of protective immunity against malaria infec-
tion (Li et al. 1993, Rodrigues et al. 1994). A
similar protective immunity could not be achieved
with two doses of only recombinant influenza or
vaccinia viruses. Table VI summarizes the results
obtained using different heterologous prime-boost
immunization regimes to elicit immunological elim-
ination of liver stages of P. yoelii and protective im-
munity against malaria.
This unexpected observation was explained by
the fact that mice immunized with the combination
of these two different carrier viruses had a frequency
of epitope-specific CD8 T-cells more than 20 times
higher than animals immunized twice with one of
these recombinant viruses (Murata et al. 1996).
In figure 2 there is an example of the synergistic
effect observed after the heterologous prime-boost
immunization with recombinant influenza virus fol-
lowed by recombinant vaccinia virus expressing the
malarial epitope. As it can be noticed there is an in-
crease of more than 40 folds in the number of malaria
peptide specific CD8 T cells.
The expansion of epitope-specific CD8 T-cells
depends on the sequence of immunization with these
two viruses. In mice primed with recombinant vac-
cinia virus followed by a booster injection with re-
combinant influenza virus, the frequency of CD8
T-cells was 10 times lower than after priming with
influenza virus followed by a vaccinia virus booster
(Figure 2 and Murata et al. 1996). No protec-
tive immunity could be observed in this case (Li
et al. 1993). These findings were recently extended
to other malaria CD8 epitopes expressed in the CS
protein of P. falciparum, a human malaria parasite
(Miyahira et al. 1998).
Based on these observations, several authors
have explored the heterologous prime-boost immu-
nization to increase the CD8 immune response. In-
dependently performed studies using two distinct
rodent malaria parasites, P. yoelii and P. berghei,
observed that the heterologous prime-boost immu-
nization regimes with a plasmid containing the CS
gene followed by injection with recombinant vac-
cinia virus greatly enhanced the specific CD8 T cell
response. This protocol of immunization did not
only lead to a significant increase in the CD8 im-
mune response, but also provided a significant de-
gree of protection against a challenge with P. berghei
or P. yoelii sporozoites (Table VI and Schneider et
al. 1998, Sedegah et al. 1998).
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TABLE VI
Summary of experiments using heterologous prime/boost regimes to elicit immunological elimination of liver stages and
complete protection against challenge with Plasmodium yoelli sporozoites.
Recombinant viruses, Liver Complete Immunological Ref.
particles of DNA stage protection of mechanism of
Prime Boost inhibition BALB/c mice protection
Adenovirus Vaccinia 100% 100% CD8 and CD4 Bruna-Romero
Entire CS protein Entire CS protein T cells et al. 2001
Plasmid Vaccinia ? 80-87.5% CD8 T cells Sedegah et al. 2000
Entire CS protein Entire CS protein
+ GMCSF
Plasmid Vaccinia ? 50-69% CD8 T cells Sedegah et al. 1998
Entire CS protein Entire CS protein
TyVLPs particles Vaccinia >95% 62% CD8 T cells Oliveira-Ferreira
CD8 epitope Entire CS protein et al. 2000
Influenza Vaccinia >95% 60% CD8 T cells Li et al. 1993
CD8 epitope Entire CS protein
Influenza Vaccinia >95% ? CD8 T cells Rodrigues et al. 1994
CD8 epitope Entire CS protein
Vaccinia Influenza <10% 0% None Li et al. 1993
Entire CS protein CD8 epitope
Vaccinia Plasmid ? 13% None Sedegah et al. 1998
Entire CS protein Entire CS protein
The increase in frequency of specific CD8 cells
was dependent on the order of immunization. Prim-
ing with recombinant vaccinia virus followed by a
booster injection of DNA did not evoke a significant
increase in the frequency of specific CD8 T-cells or
protection against malaria infection (Table VI and
Schneider et al. 1998, Sedegah et al. 1998).
The immunogenicity of DNA vaccines can be
further enhanced by co-immunization with plasmids
containing genes of cytokines or co-stimulatory
molecules of the immune system. Using P. yoelii
infection, it was possible to demonstrate that co-
administration of a plasmid containing the gene of
murine GM-CSF enhanced both the CD8 response
and the protective immunity to malaria in mice im-
munized with the CS gene and subsequently boosted
with a recombinant vaccinia virus (Table VI and
Sedegah et al. 2000).
Also using murine malaria as a vaccination
model, it has been shown that priming with recom-
binant virus-like particles derived from a yeast retro-
transposon (TyVLPs) containing the P. berghei or P.
yoelii CS CD8 epitope could only induce strong CD8
T cell responses and protective immunity to malaria
when followed by a booster injection with the re-
combinant vaccinia virus expressing the P. berghei
or P. yoelii CS protein (Table VI and Plebanski et al.
1998, Oliveira-Ferreira et al. 2000).
Very recently, total inhibition of liver stage
development and 100% protection against malaria
was obtained in mice primed with the recombinant
adenovirus expressing the P. yoelii CS protein, fol-
lowed by a booster injection with a recombinant
vaccinia virus expressing this same antigen. This
protocol of immunization led to increased numbers
specific CD8 and CD4 T cells, high anti-sporozoite
antibody titers, and 100% protection of BALB/c
mice when the time between priming and boosting
with these two vectors was extended from 2 to 8
weeks. Most importantly, this immunization proto-
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Fig. 2 – Influenza Epi-CD8 – Recombinant Influenza virus con-
taining the CD8 epitope of P. yoelii CS protein (SYVPSAEQI).
Vaccinia PYCS – Recombinant Vaccinia virus containing the
entire gene of P. yoelii CS protein. Adapted from Murata et al.
1996.
col elicited long-lasting protective immunity against
experimental infection (TableVI and Bruna-Romero
et al. 2001).
In addition to malaria, similar observa-
tions have been made in several experimental mod-
els, thereby confirming the potential of the heterolo-
gous prime-boost immunization regimen to enhance
the specific immune response against multiple
pathogens (reviewed by Zavala et al. 2001). It is
also important to point out that this increase in the
frequency of specific CD8 T cells described initially
in mice was recently confirmed in several types of
non-human primates (Kent et al. 1998, Robinson et
al. 1999, Hanke et al. 1999, Allen et al. 2000).
Trypanosoma cruzi
The recent identification of epitopes recognized by
T. cruzi-specific CD8 T lymphocytes has led to stud-
ies aiming at the development of subunit vaccines
against experimental Chagas´ disease. So far, to our
knowledge, the only delivery system used to induce
T. cruzi-specific CD8 T lymphocytes was plasmid
DNA.
DNA vaccination studies were performed with
3 distinct genes of T. cruzi encoding for major sur-
face antigens of trypomastigote forms of this par-
asite. In studies conducted in our laboratory we
used a gene encoding for the catalytic domain of
the enzyme trans-sialidase (TS). Immunization of
BALB/c mice with the TS gene elicited specific an-
tibodies and promoted T-cell activation (Costa et al.
1998). The T-cell immune response was later char-
acterized as being mediated mainly by CD4 Th1
and CD8 TC1 cells, which secreted a large amount
of IFN-γ , but not IL-4 or IL-10 (Rodrigues et al.
1999). Upon challenge with infective T. cruzi try-
pomastigotes, immunized mice showed a significant
reduction in parasitemia and survived acute lethal
infection (Costa et al. 1998).
Parallel studies were performed on BALB/c
and C57BL/6 mice immunized with plasmids con-
taining the TSA-1 gene. DNA vaccination was
shown to generate antibodies, as well as CD8 T cells
specific for parasitic epitopes. After challenge with
T. cruzi trypomastigotes, a significant reduction in
parasitemia was observed in C57Bl/6 mice, but not
in BALB/c mice. Nevertheless, in both cases the
DNA-vaccinated mice were more likely to survive
acute infection than mice injected with the plasmid
vector alone (Wizel et al. 1998a).
DNA-based immunization was also performed
with a plasmid containing the gene of T. cruzi com-
plement regulatory protein. This study demon-
strated that both recombinant protein and DNA im-
munization could elicit activation of specific CD4 T
cells. However, only DNA immunization could con-
fer protective immunity on BALB/c mice. Based on
that comparison, the authors proposed that CD8 T
cell activation occurring during DNA immunization
could be important for the protective immunity ob-
served (Sepulveda et al. 2000).
Most recently, studies were carried out with
genes encoding antigens expressed by the intracellu-
lar replicative forms of T. cruzi. They demonstrated
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that the genes encoding ASP-1, ASP-2 and LYT1
could provide a high degree of protective immunity
against experimental infection (Garg and Tarleton
2002 and Fralish and Tarleton 2003).
From mice immunized with the TS gene, we
isolated CD4 Th1 and CD8 Tc1 clones which dis-
played remarkable antiparasitic activities in vitro
(Rodrigues et al. 1999, 2000b). Because DNA im-
munization with the TS gene could elicit distinct
immunological mechanisms, we considered that a
detailed comparison of the immunogenicity of plas-
mids containing either the entire TS gene or DNA se-
quences encoding its immunogenic portions would
be important. For that purpose, the levels of T cell
response and protective immunity against experi-
mental infection were evaluated in mice immunized
with plasmids containing DNA sequences encoding
either the TS CD4 or CD8 or both T-cell epitopes.
Distinct plasmids containing DNA sequences
encoding both TS CD4 and CD8 T-cell epitopes
could provide a degree of immunity sufficient
to reduce the parasitemia and mortality of DNA-
immunized animals caused by a lethal challenge
with T. cruzi. On the other hand, plasmids express-
ing either CD4 or CD8 T-cell epitopes of TS were
unable to provide a similar degree of protective
immunity against infection (Table VII). These ob-
servations suggest that activation of CD4 Th1 and
CD8Tc1 T cells are important for host immunopro-
tection induced by immunization with a DNA sub-
unit vaccine (Fujimura et al. 2001).
Toxoplasma gondii and Leishmania sp.
The fact that no clear epitope recognized by CD8 T
cells has been characterized in T. gondii or Leish-
mania sp. precludes testing of subunit vaccines in
experimental models. Several reports using plasmid
immunization have been able to demonstrate hetero-
geneous degrees of protective immunity against T.
gondii infection in immunized mice. These stud-
ies used genes encoding the antigens SAG1, GRA1,
GRA7 and ROP2.
Although DNA immunization can elicit some
degree of protective immunity, the activation of spe-
cific CD8 T cells has been poorly or not at all charac-
terized (Nielsen et al. 1999, Angus et al. 2000, Ver-
cammen et al. 2000, Desolme et al. 2000). Whether
subunit vaccines may induce protective CD8 T cells
specific for these antigen remains to be further char-
acterized in the future.
In Leishmania major, s.c. immunization with a
plasmid containing the gene coding L. major LACK
elicited protective immunity against infection in a
highly susceptible mouse strain (BALB/c). The pro-
tective immunity detected was mostly mediated by
specific CD4 Th1 cells, although protective immu-
nity was also partly dependent on CD8 T lympho-
cytes (Gurunathan et al. 1997). A further evaluation
of the role of CD8 T cells found that they may func-
tion as helpers for the development of effector CD4
T cells. No evidence so far has indicated that the
participation of CD8 T cells in protective immunity
against L. major is related to their effector function
(Gurunathan et al. 2000). Also, a CD8 T-cell epi-
tope is yet to be identified within the LACK antigen.
HUMAN CLINICAL TRIALS USING
SUBUNIT VACCINES
The successful results of preclinical vaccination
studies performed on rodent malarias have encour-
aged human phase I/IIa vaccination trials aimed at
inducing CD8 T cells specific for malaria liver stage
antigens. Phase I/IIa trials tested the safety, tolera-
bility and immunogenicity of plasmid DNA, recom-
binant viruses and synthetic peptides. Table VIII
presents a summary of the different human trials.
The human vaccination trials performed so
have provided evidence that DNA vaccines can be
successfully used to elicit a specific CD8 T cells
response (Doolan and Hoffman 2001). In the first
study, groups of 5 healthy individuals were immu-
nized with different doses of a plasmid containing
the P. falciparum CS protein gene produced under
Good Manufacturing Practice conditions. Individu-
als received 3 i.m. doses of plasmid, each consist-
ing of 20 to 2, 500µg of DNA. Specific cytotoxic
T lymphocytes (CTL) responses were detected in
2 of 5 individuals immunized with 3 doses of ei-
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TABLE VII
Requirement of DNA coding sequences for CD4 Th1 and CD8 Tc1 epitopes during
DNA immunization against experimental T. cruzi infection.
Plasmid Base pairs TS region(s) CD4 Th1 CD8 Tc1 Protective
(aminoacids) immune immune immunity
response response
pcDNA3-TS 1-3180(1-1060) Entire protein Yes Yes Yes
p154/13 1-2034(1-678) Catalytic domain Yes Yes Yes
p154/13 1-825(1-275) Part of the Yes No No
catalytic domain
(CD4 epitopes)
pCD8-epitope 1077-1101(359-367) CD8 epitope No No No




pcDNA3 None None No No No
Adapted from Fujimura et al. 2001.
TABLE VIII
Summary of the Phase I/IIa human vaccination trials carried out to elicit CD8 T-cell-mediated immunity against malaria.
Immunogen Antigen Safety and Responders / Total Reference
tolerability no. of individuals
tested (CD8 or CTL)
Plasmid P. falciparum Good 13/14 Wang et al. 2001
CS protein
Vaccinia virus P. falciparum Good 7/15 Ockenhouse et al. 1998
CS protein, TRAP, LSA1,
MSP1, SERA, AMA1
and Pfs25
Synthetic peptide P. falciparum Good 6/8 Lopez et al. 2001
CS protein
(amino acids 282-383)
ther 20 or 100µg of DNA. The higher immunizing
doses (500 and 2, 500µg of DNA) generated a CTL
response in 3 of 5 and 4 of 5 individuals, respec-
tively. MHC-restricted CD8 T-cells mediated CTL
activity. CTL responses were significantly higher in
individuals who received either 500 or 2, 500µg of
DNA. However, no difference was observed in the
magnitude of the CTL response after 3 doses in indi-
viduals immunized with these two doses of DNA. In
general, the CTL responses were stronger in DNA-
immunized vaccinees compared to individuals nat-
urally exposed to P. falciparum infection (Wang et
al. 1998).
A second human trial was designed to
test immune responses induced by different routes
of immunization. Individuals received three doses
of 2.5 mg of DNA i.m. by needle injection or i.m.
by needle-less BiojectorTM 2000, or i.m. and i.d.
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by BiojectorTM 2000 (70% of the total dose i.m.
and 30% i.d.). Thirteen of the 14 volunteers had
antigen-specific CD8 T cells that produced IFN-γ
responses against 20-100% of peptides containing
defined class I binding epitopes. The data also sug-
gested that Biojector injection i.m. was the most
effective route of immunization (Wang et al. 2001).
Current studies are being performed to im-
prove cell-mediated immune responses by the co-
administration of a plasmid containing the human
GM-CSF gene. Also, individuals are being immu-
nized with several plasmids containing different
malarial genes. Results of these new trials are ex-
pected to be published soon (reviewed by Doolan
and Hoffman 2001).
Phase I/IIa trials have also been performed with
NYVAC-Pf7, a highly attenuated vaccinia virus con-
taining 7 P. falciparum genes inserted into its
genome. The vaccine was considered to be safe
and well tolerated. Seven of the 15 individuals that
received three doses of 10E8 virus developed a de-
tectable CTL response to at least one of the three
liver stage antigens (CS or LSA-1 or TRAP antigen,
Ockenhouse et al. 1998). Nevertheless, it is impor-
tant to notice that the individuals immunized were
not HLA matched. Therefore, it is difficult to deter-
mine whether the absence of the immune response
reflected variable immunogenicity of the vector or
lack of CD8 T-cell epitopes.
In a third Phase I/IIa vaccination trial, indi-
viduals were immunized with a synthetic peptide
representing the C-terminal region of the P. falci-
parum CS protein (amino acids 282-383). Individ-
uals were immunized i.m. with the peptide in the
presence of the adjuvants Montanide 720 or Alum.
The CD8 T cell immune response was evaluated in
HLA-A*0201 individuals. Upon vaccination, 6 of
8 individuals developed a CD8 T lymphocyte re-
sponse, as measured by IFN-γ secretion. CD8 T
cells were mainly directed toward epitopes 327-335
(5 of 8 volunteers) and 299-308 (2 of 8 volunteers,
Lopez et al. 2001).
In a very recent publication, a heterologous
prime-boost vaccination regime of DNA either in-
tramuscularly or epidermally, followed by intra-
dermal recombinant modified vaccinia virus Ankara
(MVA), induced high frequencies of interferon
IFNγ -secreting, antigen-specific T-cell responses in
humans to a pre-erythrocytic malaria antigen,
thrombospondin-related adhesion protein (TRAP,
McConkey et al. 2003). T-cell responses induced by
the DNA vaccine priming-recombinant MVA boost-
ing produced partial protection manifested as de-
layed parasitemia after sporozoite challenge with
Plasmodium falciparum.
Taken together, these human vaccination tri-
als open new avenues for new vaccination strategies
aimed at inducing malaria-specific CD8 T cells.
EVASION OF CD8 T-CELL IMMUNE RESPONSE
Viruses are the best known class of pathogens that
use a variety of mechanisms to evade the immune
recognition by MHC class I restricted CD8 T cells.
Some of these strategies may function at the level of
the antigen presentation by infected cells such as: i)
down regulation of MHC class I expression, ii) in-
terference with cytosolic proteolysis, iii) inhibition
of peptide transport to the endoplasmic reticulum
(ER), iv) retention and destruction of MHC class
I molecules in the ER, v) presence of mutant epi-
topes that do not bind to MHC I class molecules,
etc. Under these circumstances, infected cells have
a limited amount of peptide/MHC-class I complexes
on their surface that makes them extremely difficult
to be recognized by specific CD8 T cells. A detailed
review and examples of these evasion mechanisms
can be found in Ploegh 1998.
Alternatively, escape mechanisms can interfere
with the recognition by MHC I class restricted CD8
T cells. For example, mutant viruses can be se-
lected with amino acid variations that retain bind-
ing to MHC class I molecules but result in reduced
recognition by T cells or generate antagonistic pep-
tides that inhibit activation of specific T cells by the
MHC-peptide complex (reviewed by Ploegh 1998).
Most recently, viral proteins have been de-
scribed that interfere with the effector mechanisms
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TABLE IX
Polymorphism of a human CD8 T cell epitope restricted by HLA-A*0201.
Sequence Isolates of P. falciparum No. of substitutions HLA-A*0201 binding Recognition
relative activitya (% lysisb)
YLNKIQNSL NF54, 427 0 0.12 100
YLKKIKNSI 7G8 3 <0.03 9
YLKKIQNSL WEL, It2G1, T9-101, T4R 1 0.25 83
YLKTIQNSL LE5 2 0.03 0
YLKTIKNSL T9-98, 366a, 399, 406, 419 3 0.10 10
YLQKIQNSL 366b 1 0.20 91
YLQKIKNSL 406, 419 2 0.30 22
YLNTIQNSL 427 1 0.20 4
YLQKIRNSL 366c 2 0.28 14
Adapted from Bonelo et al. 2000. a = Relative activity in relation to the binding of MA influenza virus peptide. b = Percent
maximal lysis induced by a human CD8 T cell clone specific for peptide YLNKIQNSL.
mediated by T cells. For example, poxviruses en-
code several soluble cytokine receptors that bind to
and block the activity of IFN-α, β and γ TNF, IL-
1 etc. Also, these viruses express a protein termed
crmA that functionally inhibits Asp-specific cys-
teine proteases (caspases), blocking apoptosis in-
duced by CTL, TNF, or Fas (reviewed by Ploegh
1998).
It is unknown whether protozoan parasites have
evolved in such a way as to use all these mechanisms
of immune evasion. So far very few examples of
mechanisms of evasion have been confirmed in the
case of the CD8 T cell-mediated immune response
to parasites. This lack of information most likely re-
flects the fact that the CD8 T cell-mediated immune
response to parasites only recently has attracted the
attention of most investigators.
Amino acid variations in CD8 epitopes within
the CS protein of P. falciparum malaria parasites
have been described. These amino acid substitu-
tions affected binding to HLA I class molecules,
generated peptides that failed to stimulate specific
CD8 T cells or behaved as antagonistic peptides (Ud-
hayakumar et al. 1997, Gilbert et al. 1998, Bonelo
et al. 2000).
The best described example that a variation in a
malaria parasite epitope may interfere with binding
to HLA I class molecules or fail to stimulate specific
naturally induced human CD8 T cells was described
by Bonelo et al. (2000). As shown in Table IX, nine
variant peptides based on the sequences of different
strains of P. falciparum were tested for the ability
to bind to HLA-A*0201 and to be recognized by a
human CD8 T cell clone obtained from an individual
naturally exposed to the parasite.
Variant peptides from strains 7G8 and LE5 of
P. falciparum displayed much lower binding affini-
ties for HLA-A*0201 and were not recognized by
the human CD8 T cell clone. Four other variant pep-
tides still retain the ability to bind to HLA-A*0201.
However, because of their amino acid substitutions,
they also failed to be recognized by the human CD8
T cell clone. Finally, it is noteworthy that this T
cell clone could still recognize fairly well two other
variant epitopes represented in several strains of P.
falciparum. A total of 7 of the 18 different strains
could be recognized by a single T cell clone.
This experiment illustrates that there might be
naturally occurring variant CD8 epitopes that inter-
fere with recognition of MHC class I restricted T
cells. The identification of these variant epitopes
may increase our understanding of the importance
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of certain effector immune mechanisms, and ways
in which vaccines can be best designed.
PERSPECTIVES
The knowledge that CD8 T cells are essential for ef-
ficient immunity to intracellular parasites has raised
important questions with basic and applied impli-
cations. Several gaps in basic knowledge are ex-
pected to be filled in the years to come. Some of
the most relevant questions are: i) How are specific
CD8 T cells induced and maintained in vivo? ii)
What are the main effector mechanisms operating
in vivo against the different parasites? Are there
specific or general mechanisms of immune evasion
used by each of these parasites? These questions in
humans are even more relevant and still more com-
plex to study due to the obvious limitations.
From the applied point of view, it is now clear
that the heterologous prime-boost regimes of im-
munization can be highly efficient in terms of the
expansion of protective CD8 T lymphocytes. Nev-
ertheless, the reason why this type of immunization
is more efficient than the others is still largely un-
known and should be addressed in the future. To
our knowledge, few hypotheses have been formu-
lated thus far to explain this event and none was
tested experimentally with success.
Finally, human vaccination trials aimed at in-
ducing CD8 T cell-mediated immunity have been
initiated and should be further intensified to pro-
vide important information about the feasibility of
this strategy to develop a new generation of vaccines
against parasitic infections.
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RESUMO
Parasitas intracelulares obrigatórios como Plasmodium
sp, Trypanosoma cruzi, Toxoplasma gondii e Leishmania
sp são responsáveis pela infecção de milhões de indiví-
duos a cada ano. Estes parasitas são capazes de liberar an-
tígenos no citoplasma de células infectadas do hospedeiro
que são apresentados por moléculas de MHC classe I
para células T CD8 protetoras. As condições de estí-
mulo in vivo destas células T CD8 específicas durante a
infecção natural são pouco conhecidas e constituem uma
área pouco explorada. Os mecanismos anti-parasitários
mediados por células T CD8 incluem vias dependentes
e independentes do interferon-γ . O fato que células T
CD8 são potentes inibidores do desenvolvimento para-
sitário levou diversos investigadores a explorarem se a in-
dução destes linfócitos T poderia constituir uma estratégia
factível para o desenvolvimento de vacinas efetivas con-
tra estas doenças parasitárias. Estudos feitos em modelos
experimentais suportam a hipótese que células T CD8 in-
duzidas por vetores recombinantes virais ou vacinas de
DNA podem servir de base para a vacinação humana.
Regimes de imunização consistindo de dois vetores dis-
tintos (prime-boost heterólogo) são muito mais eficientes
em termos da expansão de linfócitos T CD8 protetores do
que a imunização com um único vetor. Os resultados obti-
dos usando modelos experimentais levaram a vacinações
clínicas que estão atualmente em curso.
Palavras-chave: CD8, parasitas, imunidade, vacinas.
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